Clinical trials: Opioid Induced Constipation (OIC)
Chronic Severe Pain
A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment
This non-interventional, observational study evaluates the efficacy of Targinact with regard to quality of life in daily clinical practice in Belgium compared to the previous analgesic treatment.
- Trial name
- NCT01710917
- Testing
- Targinact® (oxycodon/naloxon)
- Where
- Belgium
- Volunteers
- 1,800 people
- Sponsor
- Mundipharma CVA
Constipation, Cancer
Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
This is a study to compare the efficacy and tolerability of two laxatives for treatment of opioid-induced constipation in adult outpatients with cancer treated at the British Columbia Cancer Pain and Symptom Management/Palliative…
- Trial name
- NCT01189409
- Testing
- PEG then Senna, Senna then PEG
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- British Columbia Cancer Agency
Constipation
Methylnaltrexone for Opioid Induced Constipation
Methylnaltrexone for the treatment of opioid-induced constipation in the setting of palliative or hospice care, is significantly more effective than placebo (1).
- Trial name
- RILAX (NCT01955213)
- Testing
- methylnaltrexone
- Where
- 6 sites in Netherlands
- Volunteers
- 7 people
- Sponsor
- Amsterdam UMC, location VUmc
Opioid Induced Constipation
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
This is a single-arm, open label, multinational, multicentre, prospective, real world observational study of Naloxegol in adult subjects with Opioid Induced Constipation (OIC) in patients receiving Naloxegol in routine clinical…
- Trial name
- NACASY (NCT03638440)
- Testing
- Naloxegol
- Where
- 10 sites in Denmark, Finland and 8 more
- Volunteers
- 183 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Constipation
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01275755
- Testing
- ADL5945 0.25 mg
- Volunteers
- 81 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid-Induced Constipation
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
The purpose of this study was to evaluate the safety and efficacy of linaclotide for the treatment of opioid-induced constipation (OIC), in adults receiving stable opioid treatment for chronic non-cancer pain that has been…
- Trial name
- NCT02270983
- Testing
- Linaclotide 145 micrograms, Linaclotide 290 micrograms
- Where
- 77 sites in United States
- Volunteers
- 254 people
- Sponsor
- Forest Laboratories
Opioid-induced Constipation
ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
The purpose of this study is to assess the safety and tolerability of RDC-1036 (ALKS 37) in adults with opioid-induced constipation (OIC) following repeat dose administration
- Trial name
- NCT01100151
- Testing
- RDC-1036 (ALKS 37)
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alkermes, Inc.
Opioid-Induced Constipation
Colonic Motor Patterns in Healthy Volunteers
Characterization of motor patterns with opioid agonists (codeine) ingestion, and their reversal by a peripherally acting mu-opioid receptor antagonist (Naloxegol).
- Trial name
- NaloxegolHRM (NCT05770960)
- Testing
- Naloxegol, codeine phosphate
- Where
- Belgium
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
OIC
RELISTOR's Effects on Opioid-Induced Constipation
This will be a prospective case-control study of 40 patients undergoing 1-2 level ALIF procedures at Methodist Dallas Medical Center (MDMC).
- Trial name
- NCT04930237
- Testing
- Relistor Injectable Product, Docusate Calcium, Bisacodyl
- Where
- United States
- Sponsor
- Methodist Health System
Neoplasms, Constipation
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
- Conditions
- Neoplasms, Constipation, Opioid-Related Disorders
- Trial name
- NCT01004393
- Testing
- Methylnaltrexone bromide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Vermont
Constipation
Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
This study is designed to evaluate the long-term safety and tolerability of the subcutaneous (SC) injection form of N-methylnaltrexone bromide (MOA-728) for the treatment of opioid-induced constipation in participants with…
- Trial name
- NCT00804141
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 120 sites in United States, Australia and 4 more
- Volunteers
- 1,040 people
- Sponsor
- Bausch Health Americas, Inc.
Cancer, Constipation
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
The purpose of this study is to determine if naloxegol can be used in the treatment of opioid-induced constipation in patients with cancer and pain.
- Conditions
- Cancer, Constipation, Pain
- Trial name
- NCT02839889
- Testing
- Naloxegol
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Hospice of Henderson County, Inc.
Constipation
Naloxegol in Cancer Opioid-Induced Constipation
The purpose of this study is to compare the effect of naloxegol versus the patient's usual care in treating opioid-induced constipation, as well as the effect on the patient's quality of life and how much pain is experienced.
- Trial name
- NCT02745353
- Testing
- naloxegol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Joseph Ma
Opioid-induced Constipation, Cancer
Study of Opioid-Induced Constipation 1 Project
The aim of the project is to investigate opioid-induced constipation (OIC) in a real world / diverse group of patients with cancer.
- Conditions
- Opioid-induced Constipation, Cancer, Cancer Pain
- Trial name
- StOIC-1 (NCT04350112)
- Testing
- Clinical assessment
- Where
- 16 sites in United Kingdom
- Volunteers
- 1,007 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Opioid-induced Constipation in Patients With Cancer
Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer
Approximately 70-80% of patients with advanced disease will be affected by moderate to severe pain. Opioid analgesics represented by morphine and oxycodone are the cornerstone of cancer-pain management, and recommended for use in…
- Trial name
- NCT03797586
- Testing
- Electroacupuncture group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Opioid-induced Constipation
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.
- Trial name
- NCT01965158
- Testing
- Naldemedine
- Where
- 65 sites in United States, Austria and 5 more
- Volunteers
- 547 people
- Sponsor
- Shionogi
Opioid-Induced Constipation (OIC)
Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive…
- Trial name
- NCT05588323
- Testing
- Naldemedine
- Where
- 16 sites in Albania, Armenia and 6 more
- Volunteers
- 24 people
- Sponsor
- Shionogi
Opioid Use, Constipation Drug Induced
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
Opioid-Induced Constipation (OIC) is often associated with a compromised quality of life of patients in palliative care (PC) setting.
- Conditions
- Opioid Use, Constipation Drug Induced, Cancer
- Trial name
- NCT04294550
- Testing
- Naloxegol
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione ANT Franco Pannuti ETS
OIC
ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
The purpose of this study is to evaluate the safety and efficacy of ALKS 37 when administered daily to adults with OIC.
- Trial name
- NCT01418092
- Testing
- ALKS 37
- Where
- 13 sites in United States
- Volunteers
- 91 people
- Sponsor
- Alkermes, Inc.